WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
SHANGHAI,Nov. 7,2018 -- WuXi Biologics (2269.HK),a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,development and manufacturing,today announced Dr. Chris Chen,Chief Executive Officer of WuXi Biologics,has been appointed by International Society for Pharmaceutical Engineering (ISPE) to serve on the International Board of Directors for a two-year term. Dr. Chris Chen is also the first Board member from Asia.
ISPE is the world's largest not-for-profit association serving its members by leading scientific,technical and regulatory advancement throughout the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe,effective pharmaceutical and biologic medicines,and medical delivery devices in more than 90 countries around the world. In March 2014,WuXi Biologics' drug substance facility received the Honorable Mention Award "Facility-of-the-Year" from ISPE,a first for China.
"ISPE strives to improve manufacturing of quality medicines for global patients. I'm honored and proud to be part of ISPE's Board to engage in the governance and strategic direction of the Society,which is a great opportunity for me personally as well as WuXi Biologics," said Dr. Chris Chen.
On November 4,2018,ISPE Annual Meeting was held in Philadelphia,Pennsylvania USA,where members who had been elected to serve on the new Board formally took office. Dr. Chris Chen gave a keynote speech of "Biomanufacturing Facilities of the Future: the WuXi Biologics Story". During the speech,Dr. Chris Chen highlighted the pioneering scale-out strategy using disposable bioreactors to produce biologics at commercial scale and WuXi Biologics' investment in developing continuous biomanufacturing process to reduce manufacturing cost and ensure affordability. Other keynote speakers included Mr. Lars Fruergaard Jorgensen,President and CEO of Novo Nordisk,Mr. Kevin Nepveux,Vice President of Pfizer Global Supply,Ms. Becky Furuta,Team Novo Nordisk Diabetes Cycling Team and Health Care Policy Consultant,and Mr. Nick Leschly,CEO of Bulebird Bio. More than 1500 professionals from 28 countries including regulators from 14 countries such as theUS FDA attended this year's annual meeting.
About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association servingits members through leading scientific,technical,and regulatory advancement across the entire pharmaceutical lifecycle. The 18,and medical delivery devices in morethan 90 countries around the world. Founded in 1980,ISPE has its worldwide headquarters in Bethesda,Maryland USA,and its operations center in Tampa,Florida USA. Visit www.ISPE.org for more information.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK),a Hong Kong-listed company,is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover,develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30,there were a total of 187 integrated projects,including 98 projects in pre-clinical development stage,78 projects in early-phase (phase I and II) clinical development,10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China,Ireland,Singapore and US reaching 220,000 liters by 2021,we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics,please visit www.wuxibiologics.com.
